GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
50.19
-0.47 (-0.93%)
Sep 2, 2026, 10:25 AM EDT - Market open
GSK Revenue
GSK had revenue of 8.41B GBP in the quarter ending June 30, 2026, with 5.30% growth. This brings the company's revenue in the last twelve months to 33.20B, up 4.97% year-over-year. In the year 2025, GSK had annual revenue of 32.67B with 4.11% growth.
Revenue (ttm)
33.20B GBP
Revenue Growth
+4.97%
P/S Ratio
2.30
Revenue / Employee
496,746 GBP
Employees
66,841
Market Cap
101.45B USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.67B | 1.29B | 4.11% |
| Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
| Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
| Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
| Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
| Dec 31, 2020 | 24.35B | -9.40B | -27.85% |
| Dec 31, 2019 | 33.75B | 2.93B | 9.52% |
| Dec 31, 2018 | 30.82B | 635.00M | 2.10% |
| Dec 31, 2017 | 30.19B | 2.30B | 8.24% |
| Dec 31, 2016 | 27.89B | 3.97B | 16.58% |
| Dec 31, 2015 | 23.92B | 917.00M | 3.99% |
| Dec 31, 2014 | 23.01B | -3.50B | -13.20% |
| Dec 31, 2013 | 26.51B | 74.00M | 0.28% |
| Dec 31, 2012 | 26.43B | -956.00M | -3.49% |
| Dec 31, 2011 | 27.39B | -1.01B | -3.54% |
| Dec 31, 2010 | 28.39B | 24.00M | 0.08% |
| Dec 31, 2009 | 28.37B | 4.02B | 16.49% |
| Dec 31, 2008 | 24.35B | 1.64B | 7.20% |
| Dec 31, 2007 | 22.72B | -509.00M | -2.19% |
| Dec 31, 2006 | 23.23B | 1.57B | 7.23% |
| Dec 31, 2005 | 21.66B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Merck & Co. | 66.57B |
| AbbVie | 64.39B |
| Pfizer | 63.70B |
| AstraZeneca | 61.37B |
| Novartis AG | 56.69B |
| Sanofi | 55.89B |
| Novo Nordisk | 50.34B |
| Bristol-Myers Squibb Company | 49.19B |
GSK News
- 1 day ago - GSK Looks 10.0% Overvalued on GF Value⢠as Dividend Sustainability Remains Key - GuruFocus
- 1 day ago - GSK's MRNA Flu Vaccine Candidate Advances To Phase III Trial - Nasdaq
- 1 day ago - GSK Looks 10.1% Overvalued on GF Value⢠as Dividend Sustainability Remains Key - GuruFocus
- 1 day ago - GSK to advance mRNA flu vaccine to late-stage trial - Reuters
- 5 days ago - Noteworthy ETF Outflows: FENI, GSK, UL, SHEL - Nasdaq
- 6 days ago - GSK: ViiV Healthcare Secures FDA Approval For Tivicay PD In Young Children With HIV - Nasdaq
- 6 days ago - GSK Looks 13.2% Overvalued on GF Value⢠as Dividend Sustainability Remains Key - GuruFocus
- 6 days ago - GSK Looks 14.4% Overvalued on GF Value⢠Amid New HIV Treatment Approval - GuruFocus